Loading
Total declarations
Company
▲ Purchases (56 ops.)
▼ Sales (114 ops.)
Latest filing published 09 Apr 2026 for Clover Biopharmaceuticals, Ltd. - B. Read the official filing
Filing timeline
BuySaleLiang Joshua G
Insider track record
Disclosed buys
56
Disclosed sells
114
Signal history
Closed purchases
Market purchases
56
Positive at T+90
0%
Median T+90
-39.9%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -49.8%Entry HK$3.08 · Close 20 Oct 2026 HK$1.54
- -49.3%Entry HK$3.05 · Close 20 Oct 2026 HK$1.54
- -45.8%Entry HK$2.85 · Close 20 Oct 2026 HK$1.54
- -80.7%Entry HK$1.17 · Close at T+365 HK$0.23
- -80.2%Entry HK$1.21 · Close at T+365 HK$0.24
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Liang Joshua G: trading record in brief
Liang Joshua G (chief executive) discloses dealings in Clover Biopharmaceuticals, Ltd. - B to HKEX. We count 191 filings; the first trade dates from 5 November 2021 and the latest from 2 April 2026.
Market trades split into 56 purchases (€208k) and 114 sales. The totals exclude 168 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 4 purchases and 2 sales.
Across 5 purchases, this insider has always bought alone, with no colleague buying within 30 days.
On 9 April 2026 came the latest disclosure, an open-market sale in Clover Biopharmaceuticals, Ltd. - B. The most recent open-market purchase was published on 9 April 2026, 195 days ago. Typically, a trade is published a median of 2 days after it takes place. Until a filing is published, the market cannot know about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Companies and markets linked to Liang Joshua G
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations191 total
1,086,000 sharesShareXHKGHKEX:DA20260409E00098
2,412,875 sharesShareXHKGHKEX:DA20260409E00096
383,000 sharesShareXHKGHKEX:DA20260409E00099
Canonical exit: 1 Jul 2026 (T+90)
9,840 sharesShareXHKGHKEX:DA20260403E00017
Canonical exit: 29 Jun 2026 (T+90)
6,577,500 sharesShareXHKGHKEX:DA20260401E00050
Canonical exit: 25 Jun 2026 (T+90)
616,000 sharesShareXHKGHKEX:DA20260122E00392
1,551,125 sharesShareXHKGHKEX:DA20260122E00385
8,844 sharesShareXHKGHKEX:DA20260106E00006
Canonical exit: 31 Mar 2026 (T+90)
220,000 sharesShareXHKGHKEX:DA20251015E00514
Canonical exit: 13 Jan 2026 (T+90)
8,844 sharesShareXHKGHKEX:DA20251003E00372
Canonical exit: 29 Dec 2025 (T+90)
276,500 sharesShareXHKGHKEX:DA20250729E00075
Canonical exit: 23 Oct 2025 (T+90)
816,500 sharesShareXHKGHKEX:DA20250729E00073
Canonical exit: 22 Oct 2025 (T+90)
8,844 sharesShareXHKGHKEX:DA20250703E00294
Canonical exit: 28 Sept 2025 (T+90)
70,053 sharesShareXHKGHKEX:DA20250418E00040
Canonical exit: 14 Jul 2025 (T+90)
23,000 sharesShareXHKGHKEX:DA20250418E00039
227,479 sharesShareXHKGHKEX:DA20250418E00038
6,577,500 sharesShareXHKGHKEX:DA20250408E00464
Canonical exit: 1 Jul 2025 (T+90)
269,250 sharesShareXHKGHKEX:DA20250408E00462
Canonical exit: 1 Jul 2025 (T+90)
71,500 sharesShareXHKGHKEX:DA20250408E00455
768,500 sharesShareXHKGHKEX:DA20250408E00453
9,844 sharesShareXHKGHKEX:DA20250408E00473
Canonical exit: 29 Jun 2025 (T+90)
6,204,500 sharesShareXHKGHKEX:DA20250408E00451
Canonical exit: 20 Apr 2025 (T+90)
9,844 sharesShareXHKGHKEX:DA20250403E00049
Canonical exit: 29 Jun 2025 (T+90)
69,990 sharesShareXHKGHKEX:DA20250120E00014
Canonical exit: 15 Apr 2025 (T+90)
105,000 sharesShareXHKGHKEX:DA20250120E00013
25 of 191 declarations
